Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure, in Obese, Insulin-Resistant Rhesus Monkeys

@article{Kemnitz1994PioglitazoneII,
  title={Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure, in Obese, Insulin-Resistant Rhesus Monkeys},
  author={J. Kemnitz and D. Elson and E. Roecker and S. Baum and R. Bergman and M. Meglasson},
  journal={Diabetes},
  year={1994},
  volume={43},
  pages={204 - 211}
}
The antidiabetic effects of pioglitazone hydrochloride were evaluated in 6 spontaneously obese, insulin-resistant rhesus monkeys. The animals were studied during six successive 2-wk treatment phases separated by 2-wk rest periods: two placebo phases; 0.3, 1.0, and 3.0 mg · kg−1 · day−1 pioglitazone hydrochloride phases; and a final placebo phase. During the second week of each treatment phase, serum insulin (immunoreactive insulin [IRI]), plasma glucose, and serum triglyceride (TG) levels were… Expand
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
TLDR
Pioglitazone significantly decreased fasting and postprandial insulin concentrations and effectively lowered blood pressure in the spontaneously hypertensive rat (SHR), suggesting the possibility that insulin resistance and hyperinsulinemia may play an important role in blood pressure regulation. Expand
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
TLDR
It is suggested that pioglitazone therapy in type 2 diabetic patients decreases lasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin. Expand
Pioglitazone Increases Whole Body Insulin Sensitivity in Obese, Insulin-Resistant Rhesus Monkeys
TLDR
A physiological clamp paradigm (similar to humans) for assessing glucose turnover in NHPs is determined and it is demonstrated that insulin-resistant, dysmetabolic NHPs respond to the established insulin sensitizer, pioglitazone, thus confirming their use as an ideal pre-clinical translational model to assess insulin sensitizing compounds. Expand
Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
TLDR
It is suggested that metformin-induced improvement of insulin resistance in obese rats with NIDDM may lower blood pressure, as well as decrease sympathetic activity and reduce body weight. Expand
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
TLDR
improved insulin resistance and glycemic control, as well as Tg and HDL‐C–which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes. Expand
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
TLDR
It is indicated that pioglitazone enhances the insulin action in NIDDM patients on diet alone or SU, and thereby improves both plasma glucose level and lipid profiles. Expand
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
TLDR
Pioglitazone improves glycemic control through the dose-dependent enhancement of beta-cell function and improved whole-body and hepatic insulin sensitivity in patients with type 2 diabetes. Expand
A Thiazolidinedione Improves In Vivo Insulin Action on Skeletal Muscle Glycogen Synthase in Insulin-Resistant Monkeys
TLDR
It is concluded that the TZD R-102380 improves insulin action at the skeletal muscle in part by increasing the activity of glycogen synthase, a key factor in the anti-diabetic effect of the thiazolidinedione class of agents. Expand
Metformin Decreases Blood Pressure and OLETF Rats Via Improvement of Insulin Obesity in Resistance
pendent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia. Oral administration of metformin ameliorated glucose intolerance and attenuated the insulin responseExpand
Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats.
TLDR
Treatment with troglitazone was found to increase whole-body insulin sensitivity in sucrose- and chow-fed rats, but had no effect on skeletal muscle glucose transport activity measured in isolated muscles from both dietary groups. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
TLDR
It is suggested that pioglitazone can improve glucose and lipid metabolism by reducing insulin resistance on the post-binding system, and may be efficacious for treating human NIDDM. Expand
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
TLDR
Results indicate that pioglitazone is effective on abnormal glucose and lipid metabolism associated with insulin resistance by enhancing insulin action on peripheral tissues, and is expected to be useful in treating obese non-insulin-dependent diabetes. Expand
Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus.
TLDR
It is concluded that disproportionate proinsulinemia is a manifestation of B-cell damage from streptozocin which is not exacerbated by insulin resistance or hyperglycemia. Expand
Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
TLDR
Pioglitazone is expected to be useful for treating abnormal glucose and lipid metabolism in non-insulin-dependent diabetes mellitus through reducing insulin resistance of the peripheral tissues and liver. Expand
Role of Insulin Resistance in Human Disease
TLDR
The possibility is raised that resistance to insulin-stimulated glucose uptake and hyperinsulinemia are involved in the etiology and clinical course of three major related diseases— NIDDM, hypertension, and CAD. Expand
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
TLDR
It appeared that pioglitazone acted to restore sensitivity to insulin's normal inhibitory actions, and this was consistent with a role for liver GLUT2 in bidirectional transport of glucose during physiological states of uptake or release. Expand
Insulin levels, physical activity, and urinary catecholamine excretion of obese and non-obese rhesus monkeys.
TLDR
The results suggest that hyperinsulinemia associated with obesity in rhesus monkeys is linked to increased catecholamine secretion and a resistance to catechlaminergic action. Expand
Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase
TLDR
The results suggested that pioglitazone increased insulin sensitivity in part by activating kinase of the receptors through indirect effect on insulin receptors and that the drug may have useful benefits in insulin resistance of NIDDM. Expand
Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent
TLDR
Results show that ADD-3878 is effective on abnormal glucose and lipid metabolism associated with insulin resistance or obesity through reduction of peripheral insulin resistance and is expected to be useful in the treatment of hyperglycemie, hyperinsulinemia, and hyperlipemia in obese type II diabetes and Obesity. Expand
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
TLDR
The proposed model of insulin/C-peptide kinetics, derived from the original conception of Eaton and Polonsky, suggests that in healthy individuals, there is a balance between secretion and insulin action such that insulin secretion × insulin sensitivity = constant, and supports the concept that, at physiological insulin levels, the time for insulin to cross the capillary endothelium is the process that determines the rate of insulin action in vivo. Expand
...
1
2
3
4
...